Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Comment by Ingiboyon Nov 07, 2024 12:56pm
91 Views
Post# 36301383

RE:RE:Meeting date Dec 30

RE:RE:Meeting date Dec 30AS and his gang have little to no interest in meeting with the shareholders.  Because Replicel is still a publicly traded company at this point they are by law obligated to hold an AGM. At this AGM they will be presenting this takeover proposal for voting by the shareholders.  We as minority shareholders have little chance of voting this down.   
Will they be presenting the "plan"  at the meeting ?   I predict it will be a very vague description on how the company will move forward mainly because I don't think there is a long term plan.  I think that once his company gains control of the Replicel assets and the public version of the company is folded the assets will be sold off.  Hopefully they get a reasonable return for them.  At this point we have no idea what they are worth or who might be interested.  All I know is I have no interest in selling my shares for $.01 like some other shareholders that are done and moving on.

<< Previous
Bullboard Posts
Next >>